Tech Center 1600 • Art Units: 1651
This examiner grants 41% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18378530 | FUNCTIONAL CORTICAL ORGANOIDS, METHODS OF MAKING, AND USES THEREOF | Final Rejection | The Regents of the University of California |
| 18190660 | Using Water Ponds for Capturing Dioxide and Growing Algae | Final Rejection | Saudi Arabian Oil Company |
| 17425039 | MICROCARRIER FOR CELL CULTURE, METHOD FOR PRODUCING THE SAME, AND CELL CULTURE METHOD USING THE SAME | Final Rejection | LG CHEM, LTD. |
| 18067901 | Method and Apparatus for Electroporation of Acoustically-Aligned Cells | Final Rejection | The Charles Stark Draper Laboratory, Inc. |
| 18368888 | METHOD FOR ENHANCING IMMUNE SYSTEM FUNCTIONS IN A SUBJECT | Non-Final OA | Macularity, Inc. |
| 18909731 | SYSTEM AND METHOD FOR AGGREGATION AND AUTOLOGOUS USE OF ALPHA 2M MOLECULES TO TREAT RESPIRATORY CONDITIONS | Non-Final OA | REVIVAL ANIMAL HEALTH, LLC |
| 18909762 | SYSTEM AND METHOD FOR ALLOGENEIC OR XENOGENEIC USE OF ALPHA 2M MOLECULES IN TREATING MEDICAL CONDITIONS | Non-Final OA | REVIVAL ANIMAL HEALTH, LLC |
| 18424552 | SYSTEM AND METHOD FOR ALLOGENEIC OR XENOGENEIC USE OF ALPHA 2M MOLECULES IN TREATING MEDICAL CONDITIONS | Non-Final OA | REVIVAL ANIMAL HEALTH, LLC |
| 18535841 | SYSTEM AND METHOD FOR ISOLATION AND AUTOLOGOUS USE OF ALPHA 2M MOLECULES TO TREAT RESPIRATORY CONDITIONS | Non-Final OA | REVIVAL ANIMAL HEALTH, LLC |
| 18215498 | SYSTEM AND METHOD FOR ISOLATING ALPHA 2M MOLECULES | Non-Final OA | REVIVAL ANIMAL HEALTH, LLC |
| 18486269 | INTEGRATED SYSTEM FOR MULTIPLE CULTIVATIONS OF A BIOLOGICAL AGENT AND METHODS OF USE THEREOF | Non-Final OA | City University of Hong Kong |
| 18015207 | COMPOSITION FOR PREDICTING OR DIAGNOSING EARLY-STAGE DIFFUSE GASTRIC CANCER, COMPRISING PREPARATION FOR MEASURING LEVEL OF PEPSINOGEN II | Non-Final OA | Seoul National University Hospital |
| 18044453 | METHOD OF PRODUCING PROCESSED PROTEIN | Final Rejection | AMANO ENZYME INC. |
| 16488149 | COMPOSITIONS AND METHODS FOR TREATMENT OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)-RELATED DISORDERS | Final Rejection | CRISPR Therapeutics AG |
| 18575683 | NANOPARTICLES FOR THE CONTROL OF ONE-POT MULTI-ENZYMATIC REACTIONS | Non-Final OA | UNIVERSITÀ DEGLI STUDI DELL'INSUBRIA |
| 18534083 | BALANCED SYSTEM AND METHOD FOR PRODUCTION OF MICROBIAL OUTPUT | Non-Final OA | Tenfold Technologies, LLC |
| 18288012 | Glycosylated Opioids | Non-Final OA | River Stone Biotech ApS |
| 18288010 | USE OF PLASMODIUM IN PREPARATION OF ANTI-TUMOR PREPARATION FOR USE IN COMBINATION WITH RADIOTHERAPY | Non-Final OA | CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. |
| 18556496 | MARKERS OF AUTOIMMUNE DISEASES | Non-Final OA | ASSISTANCE PUBLIQUE – HOPITAUX DE PARIS |
| 18556227 | A Triple Co-Culture System for Drug Screening of Patient-Derived Cancer Cells and Methods of Use | Non-Final OA | Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) |
| 18380230 | METHOD OF IDENTIFYING THE SUBTYPE OF ACUTE LYMPHOBLASTIC LEUKEMIA WITH KMT2A GENE REARRANGEMENT | Non-Final OA | Uniwersytet Medyczny w Lodzi |
| 17017469 | METHODS OF TREATING OCULAR NEOVASCULAR DISEASES USING AAV2 VARIANTS ENCODING AFLIBERCEPT | Final Rejection | Adverum Biotechnologies, Inc. |
| 18481774 | MATERIALS AND METHODS TO IMPROVE IN VITRO TOXICITY PREDICTIONS | Non-Final OA | Lebrun Labs LLC |
| 18460688 | METHOD FOR EVALUATING CYSTINE UPTAKE ABILITY OF CELL, KIT FOR EVALUATING CYSTINE UPTAKE ABILITY OF CELL, METHOD FOR DETERMINING SELENOCYSTEINE, AND KIT FOR DETERMINING SELENOCYSTEINE | Non-Final OA | DOJINDO LABORATORIES |
| 17286449 | ADAPTATION AND PROCESS OPTIMIZATION OF MICROORGANISMS FOR GROWTH IN HEMICELLULOSIC DERIVED CARBOHYDRATES | Non-Final OA | MARA RENEWABLES CORPORATION |
| 18265659 | EXPRESSION VECTORS COMPOSITION | Non-Final OA | MAAVRX LTD |
| 17494690 | MODULATING ISCHEMIC INJURY | Final Rejection | Noveome Biotherapeutics, Inc. |
| 17905083 | DEVICES AND COMPONENTS FOR AUTOMATED TISSUE PROCESSING AND STAINING AND USES THEREOF | Non-Final OA | GUIZHOU MEIXINDA MEDICAL TECHNOLOGIES CO., LTD. |
| 17594440 | COMPOSITIONS OF EXOSOMES AND AAV | Final Rejection | Evox Therapeutics Ltd. |
| 17409962 | METHOD AND COMPOSITION AGAINST VIRUS INFECTIONS WITH ACTIVATED INNATE LYMPHOID CELLS (ILCS) | Final Rejection | The United States of America, as represented by the Secretary, Department of HHS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy